Marksans Pharma Ltd Quarterly Results

Q1 FY26-27 Results Summary

Revenue

The revenue stands at ₹840.80 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 1.79 per cent from ₹856.11 crore. This corresponds to a year-on-year *(YoY) growth of 35.62 per cent.

Operating Profit

Operating Profit stands at ₹213.04 crore, reflecting a quarter-on-quarter *(QoQ) increase of 9.02 per cent from ₹195.42 crore. This corresponds to a year-on-year *(YoY) growth of 112.78 per cent.

PBDT

PBDT stands at ₹231.43 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.18 per cent from ₹224.29 crore. This corresponds to a year-on-year *(YoY) growth of 132.13 per cent.

Profit Before Tax

Profit Before Tax stands at ₹206.57 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.29 per cent from ₹200.00 crore. This corresponds to a year-on-year *(YoY) growth of 169.67 per cent.

Net Profit

Net Profit stands at ₹159.41 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.97 per cent from ₹149.03 crore. This represents a 173.90 per cent year-on-year *(YoY) growth for the same year.

YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Marksans Pharma Ltd News

Marksans Pharma Ltd Earnings

YOY

QOQ

Category	Q1 FY26-27	Q1 FY25-26	Change %	FY25-26	FY24-25	Change %
Total Revenue	840.80	619.99	35.62	2,950.94	2,622.85	12.51
Expenses	627.76	519.87	20.75	2,350.16	2,090.16	12.44
Other Income	25.40	5.64	350.35	82.53	66.33	24.42
Operating Profit	213.04	100.12	112.78	683.31	599.01	14.07
Depreciation	24.86	23.10	7.62	98.63	83.39	18.28
Interest	7.00	6.07	15.32	24.13	11.66	106.95
Profit Before Tax	206.57	76.60	169.67	560.55	503.97	11.23
Tax	47.16	18.40	156.30	153.00	128.59	18.98
Net Profit	159.41	58.20	173.90	420.06	382.62	9.79

Category	Q1 FY26-27	Q1 FY25-26	Change %	FY25-26	FY24-25	Change %
Total Revenue	321.19	319.73	0.46	1,341.48	1,174.37	14.23
Expenses	239.08	249.68	-4.25	1,017.91	966.28	5.34
Other Income	17.47	2.01	769.15	103.53	65.79	57.36
Operating Profit	289.20	264.75	9.24	427.10	273.89	55.94
Depreciation	8.78	8.19	7.20	34.23	29.45	16.23
Interest	0.34	0.30	13.33	1.33	1.17	13.68
Profit Before Tax	90.46	63.58	42.28	391.54	243.25	60.96
Tax	21.42	15.52	38.02	86.29	52.14	65.50
Net Profit	69.04	48.06	43.65	300.70	188.27	59.72

Category	Q1 FY26-27	Q4 FY25-26	Change %
Total Revenue	840.80	856.11	-1.79
Expenses	627.76	660.69	-4.98
Other Income	25.40	35.17	-27.78
Operating Profit	213.04	195.42	9.02
Depreciation	24.86	24.29	2.35
Interest	7.00	6.31	10.94
Profit Before Tax	206.57	200.00	3.28
Tax	47.16	50.97	-7.47
Net Profit	159.41	149.03	6.97

Category	Q1 FY26-27	Q4 FY25-26	Change %
Total Revenue	321.19	361.57	-11.17
Expenses	239.08	255.58	-6.46
Other Income	17.47	27.48	-36.43
Operating Profit	289.20	341.71	-15.37
Depreciation	8.78	8.76	0.23
Interest	0.34	0.35	-2.86
Profit Before Tax	90.46	124.36	-27.26
Tax	21.42	32.44	-33.97
Net Profit	69.04	91.92	-24.89

Marksans Pharma Ltd Research Reports

Action	Target Price (₹)	Broker	Date	Reports
Data Not Found

Marksans Pharma Ltd Financial Reports

Data not available.

Marksans Pharma Ltd Stock Prices Compare with Peers

Company	1 Day	1 Week	1 Month	3 Months	6 Month	1 Year
Marksans Pharma	-4.42%	-3.60%	-13.53%	8.82%	49.39%	61.14%
Astrazeneca Phar	-0.94%	-1.46%	-4.76%	-26.69%	-30.18%	-35.67%
Jubilant Pharmo	1.23%	0.83%	-11.30%	-4.13%	-1.78%	-16.50%
Alembic Pharma	-2.81%	-3.73%	-11.17%	-6.84%	-0.69%	-17.14%
Concord Biotech	-2.55%	-3.08%	-11.86%	-2.24%	16.21%	-15.74%
Corona Remedies	0.68%	1.79%	0.03%	-1.88%	21.87%	42.97%
Akums Drugs	-1.89%	-3.54%	-16.51%	-1.15%	25.68%	43.72%

Marksans Pharma Ltd Corporate Information

CMD & Executive Director: Mark Saldanha

Whole Time Executive Director: Sandra Saldanha

Non Independent Executive Director / WTD: Varddhman Vikramaditya Jain

Independent Non Exe. Director: Digant Mahesh Parikh

Independent Non Exe. Director: Abhinna Sundar Mohanty

Non-Exec & Non-Independent Dir: Sunny Sharma

Independent Non Exe. Director: Shailaja Vardhan

Independent Non Exe. Director: Srinivas Mishra

Company Sec. & Compli. Officer: HARSHAVARDHAN PANIGRAHI

Marksans Pharma Ltd News

Data Not Available